April 30, 2020

Clinical Reports

  • Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease
    Authors report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms.

Antiviral Therapeutics & Vaccines

  • Adaptive COVID-19 Treatment Trial “ACTT” (NIAID)

    RESULTS (N=1063)

    • Primary Endpoint: Median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo (p<0.001)
    • Mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (NS, p=0.059) 
  • SIMPLE I Trial results (Gilead)

    RESULTS (N~400)

    • Similar improvement in clinical status for 5-day course vs 10-day course of treatment

    No placebo control

  • Remdesivir in Chinese adults with severe COVID-19

    RESULTS (237 patients were enrolled and randomly assigned to a treatment group; 158 to remdesivir and 79 to placebo)

    • Stopped prior to full enrollment due to slow patient enrollment
    • Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87–1·75]).
    • Mortality 14% Remdesivir, 13% placebo
    • Remdesivir did not result in significant reductions in SARS-CoV-2 RNA loads compared to placebo in upper respiratory tract or sputum specimens


Situation Dashboards


World Health Organization (WHO)

Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)

Johns Hopkins University (JHU)

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU

COVID-19 in US and Canada

1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources

Genomic Epidemiology COVID-19

Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.

Sources for COVID-19 Information


World Health Organization (WHO)


Centers for Disease Control, US


International Society for Infectious Diseases


This Week in Virology (TWIV)

Receive updates about Parasites without Borders initiatives, developments, and learn more about parasites by subscribing to our periodic newsletter.

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Parasites Without Borders

Un recurso educativo integral sobre todos los aspectos de las enfermedades parasitarias y su impacto en la humanidad en todo el mundo.

¡Done a los Parásitos Sin Fronteras hoy!

Ayude a llevar la información médica y biológica más reciente sobre enfermedades causadas por parásitos eucariotas a todos los médicos y estudiantes de medicina en los Estados Unidos.

Scroll al inicio